International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
- PMID: 29191513
- DOI: 10.1016/j.pan.2017.11.011
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Abstract
This statement was developed to promote international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by the National Comprehensive Cancer Network (NCCN) in 2006, but which has changed yearly and become more complicated. Based on a symposium held during the 20th meeting of the International Association of Pancreatology (IAP) in Sendai, Japan, in 2016, the presenters sought consensus on issues related to BR-PDAC. We defined patients with BR-PDAC according to the three distinct dimensions: anatomical (A), biological (B), and conditional (C). Anatomic factors include tumor contact with the superior mesenteric artery and/or celiac artery of less than 180° without showing stenosis or deformity, tumor contact with the common hepatic artery without showing tumor contact with the proper hepatic artery and/or celiac artery, and tumor contact with the superior mesenteric vein and/or portal vein including bilateral narrowing or occlusion without extending beyond the inferior border of the duodenum. Biological factors include potentially resectable disease based on anatomic criteria but with clinical findings suspicious for (but unproven) distant metastases or regional lymph nodes metastases diagnosed by biopsy or positron emission tomography-computed tomography. This also includes a serum carbohydrate antigen (CA) 19-9 level more than 500 units/ml. Conditional factors include the patients with potentially resectable disease based on anatomic and biologic criteria and with Eastern Cooperative Oncology Group (ECOG) performance status of 2 or more. The definition of BR-PDAC requires one or more positive dimensions (e.g. A, B, C, AB, AC, BC or ABC). The present definition acknowledges that resectability is not just about the anatomic relationship between the tumor and vessels, but that biological and conditional dimensions are also important. The aim in presenting this consensus definition is also to highlight issues which remain controversial and require further research.
Keywords: Anatomical definition; Biological definition; Borderline resectable; Conditional definition; Pancreatic ductal adenocarcinoma.
Copyright © 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.
Comment in
-
"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire of confusing definitions and criteria?Pancreatology. 2018 Jan;18(1):1. doi: 10.1016/j.pan.2018.01.004. Pancreatology. 2018. PMID: 29389525 No abstract available.
Similar articles
-
Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma.Pancreatology. 2020 Mar;20(2):223-228. doi: 10.1016/j.pan.2019.12.001. Epub 2019 Dec 4. Pancreatology. 2020. PMID: 31839458
-
Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.Cancers (Basel). 2018 Mar 5;10(3):65. doi: 10.3390/cancers10030065. Cancers (Basel). 2018. PMID: 29510561 Free PMC article.
-
Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria.Ann Surg Oncol. 2021 Apr;28(4):2325-2336. doi: 10.1245/s10434-020-09100-6. Epub 2020 Sep 12. Ann Surg Oncol. 2021. PMID: 32920720 Free PMC article.
-
Borderline resectable pancreatic cancer.Cancer Lett. 2016 Jun 1;375(2):231-237. doi: 10.1016/j.canlet.2016.02.039. Epub 2016 Mar 9. Cancer Lett. 2016. PMID: 26970276 Review.
-
White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.Abdom Radiol (NY). 2020 Mar;45(3):716-728. doi: 10.1007/s00261-019-02289-5. Abdom Radiol (NY). 2020. PMID: 31748823 Review.
Cited by
-
Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer.World J Clin Oncol. 2022 Jul 24;13(7):630-640. doi: 10.5306/wjco.v13.i7.630. World J Clin Oncol. 2022. PMID: 36157158 Free PMC article.
-
Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines.Mol Ther Oncol. 2024 Jun 8;32(3):200825. doi: 10.1016/j.omton.2024.200825. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39006944 Free PMC article. Review.
-
Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?Life (Basel). 2022 Mar 22;12(4):465. doi: 10.3390/life12040465. Life (Basel). 2022. PMID: 35454956 Free PMC article. Review.
-
Surgery for Pancreatic Cancer after neoadjuvant treatment.Ann Gastroenterol Surg. 2018 Sep 10;2(6):413-418. doi: 10.1002/ags3.12203. eCollection 2018 Nov. Ann Gastroenterol Surg. 2018. PMID: 30460344 Free PMC article. Review.
-
Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study.BMC Cancer. 2019 Sep 14;19(1):922. doi: 10.1186/s12885-019-6108-0. BMC Cancer. 2019. PMID: 31521134 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials